induced obesity, namely uncoupling of the endothelial nitric oxide (NO) synthase (eNOS) in PVAT.
O besity has become a global healthcare issue. The prevalence of obesity has increased exponentially in both developed and developing countries during the last decades. Such a rapid rise within this relatively short time period must result from environmental factors rather than from a change in the genome. There is clear evidence that environmental factors, such as diet and the level of physical activity, affect the risk of obesity. 1 Obesity is an established risk factor for diseases, such as type 2 diabetes mellitus, cardiovascular diseases, and many cancer types. A recent meta-analysis of 97 studies involving >2.88 million individuals and >270 000 deaths demonstrates that obesity is associated with higher all-cause mortality. 2 Abdominal adiposity is strongly and positively associated with all-cause, cardiovascular disease and cancer mortality. 3 Although major efforts are being made to attenuate such negative impacts of Western lifestyle on obesity and its sequelae, to date there are no efficient pharmacological treatment options available. 4 Obesity has numerous adverse effects on hemodynamics and cardiovascular structure and function. 5 Vascular dysfunction has been demonstrated in conduit 6 and small arteries 7 in patients with metabolic syndrome. Obese patients are more likely to develop hypertension and cardiomyopathy and have higher stroke risk. 5 Despite these facts, endothelial dysfunction is not always evident in in vitro studies. When studying the vascular function of aorta isolated from diet-induced obese mice, we found that the vasodilator response to acetylcholine remained normal in the aorta from mice fed a high-fat diet (HFD) for 20 weeks. In traditional vascular physiology studies, the surrounding adipose tissue is usually cleaned from the blood vessel. Interestingly, by leaving the aortic perivascular adipose tissue (PVAT) intact, a clear reduction in the vasodilator response to acetylcholine was observed in the aorta of obese animals as compared with lean controls. These results indicate the importance of PVAT in regulating vascular function under this condition. In the present study, we provide evidence for a novel mechanism underlying vascular dysfunction in diet
Results

Role of PVAT in Vascular Dysfunction in Diet-Induced Obese Mice
Male C57BL/6J mice were fed with either HFD or normal control diet (NCD) for 20 weeks starting at the age of 8 weeks. The HFD-treated mice developed obesity (Table) . Vasodilator response to acetylcholine was studied using aortas with or without PVAT in a wire myograph system. In aortas without PVAT, no significant differences in endothelium-dependent, NO-mediated vasodilator response to acetylcholine were found between NCD and HFD groups ( Figure 1A ). In contrast, a clear reduction in the vasodilator response to acetylcholine was observed in the aorta of obese animals compared with lean controls when PVAT was left intact ( Figure 1B) . The acetylcholine-induced vasodilation in the mouse aorta was NO-dependent because it could be completely blocked by the NO synthase inhibitor N G -nitro-l-arginine methyl ester (l-NAME; Figure 1C ). In endothelium-denuded aortic rings from control mice, acetylcholine induced a significant vasodilation if PVAT was left intact ( Figure I in the online-only Data Supplement). The PVAT-mediated vasodilation was preventable with l-NAME, indicating that PVAT-derived NO contributes to acetylcholine-induced vasodilation under normal conditions.
Reduced NO Production in PVAT of Diet-Induced Obese Mice
To directly access NO production from PVAT, time-lapse fluorescence imaging was performed with aorta sections prepared from NCD or HFD-fed mice stained with the fluorescent NO probe 4,5-diaminofluorescein diacetate. As shown in Figure 1D , basal NO production could be detected in PVAT. The PVAT NO production was enhanced by acetylcholine ( Figure 1D and 1E) and inhibited by eNOS inhibitor l-NAME, indicating the specificity of 4,5-diaminofluorescein diacetate staining. HFD-induced obesity significantly reduced the PVAT NO production, both under basal and acetylcholinestimulated conditions ( Figure 1D and 1E).
Unchanged eNOS Expression But Reduced eNOS Phosphorylation in PVAT of Diet-Induced Obese Mice
In immunohistochemistry analysis, eNOS staining was clearly positive in aortic endothelium as well as in PVAT adipocytes (Figure 2A and 2B) . In both aorta and PVAT, HFD had no significant effect on the expression of eNOS, neither on eNOS staining (Figure 2A and 2B) , nor on eNOS mRNA ( Figure II in the online-only Data Supplement) or protein ( Figure 2D ).
The expression of neuronal nNOS and inducible iNOS was not changed either ( Figure II in the online-only Data Supplement). The phosphorylation of eNOS at serine 1177 was reduced in PVAT (but not in the aorta) of HFD mice, whereas eNOS phosphorylation at threonine 495 was not changed ( Figure 2D ). Among the upstream kinases for eNOS serine 1177 phosphorylation, Akt was dephosphorylated at serine 473, whereas no changes in the adenosine monophosphate-activated protein kinase were found ( Figure 2D ).
Uncoupling of PVAT eNOS in DietInduced Obese Mice
Superoxide production was increased in PVAT of obese mice, as measured with L-012 chemiluminescence ( Figure 3A) . The enhanced ROS production in PVAT of HFD mice was reduced by NOS inhibitor l-NAME, indicating contribution of eNOS to superoxide production ( Figure 3A) . In an independent experiment with electron paramagnetic resonance technique, similar results were achieved. HFD increased superoxide production in PVAT, which was attenuated by l-NAME ( Figure 3B ), indicating eNOS uncoupling in PVAT of obese mice.
Deficiency of l-Arginine, but Not Tetrahydrobiopterin, in PVAT of Diet-Induced Obese Mice
Major mechanisms for eNOS uncoupling include deficiency of eNOS cofactor tetrahydrobiopterin (BH 4 ) and substrate l-arginine. 8, 9 Unexpectedly, the content of BH 4 in PVAT of obese mice was not reduced but increased ( Figure 4A ). The reason for this increase was likely a compensatory upregulation of GTP cyclohydrolase I, the rate-limiting enzyme for BH 4 de novo biosynthesis, selectively in PVAT ( Figure 4B and 4C). BH 4 can be oxidized to 7,8-dihydrobiopterin, and be regenerated back from 7,8-dihydrobiopterin by dihydrofolate reductase. The results that also 7,8-dihydrobiopterin content and dihydrofolate reductase expression were enhanced by HFD ( Figure 4B and 4C) indicate an accelerated turnover of BH 4 . Nevertheless, the PVAT eNOS uncoupling was unlikely to be caused by a BH 4 deficiency. Interestingly, HFD reduced the l-arginine content in PVAT ( Figure 5A ). Both arginase I and II, major l-arginine-consuming enzymes, were upregulated in the PVAT of obese mice ( Figure 5B and 5C).
Nonstandard Abbreviations and Acronyms
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Upregulation of Proinflammatory Adipokines and Cytokines in PVAT of Diet-Induced Obese Mice
Treatment with HFD led to upregulation of proinflammatory adipokines/cytokines in PVAT of obese mice, including leptin, tumor necrosis factor-α, interleukin-1β, and interferon-γ. On the other hand, anti-inflammatory adipokines/cytokines, such as adiponectin and interleukin-10, were downregulated ( Figure 
Improvement of PVAT Function by l-Arginine and Arginase Inhibitor in Diet-Induced Obese Mice
Incubation of PVAT-containing aorta from NCD mice with a combination of l-arginine (100 μmol/L) and the arginase inhibitor N ω -hydroxy-nor-arginine (10 μmol/L) for 30 minutes ex vivo in organ chamber had no effects on acetylcholine-induced vasodilation ( Figure 6 ). In contrast, the compounds markedly improved the vasodilator function of PVAT-containing aortas from HFD mice (Figure 6 ), supporting the concept of l-arginine deficiency in diet-induced obese mice.
Discussion
In the present study, we show that eNOS is expressed in PVAT, and PVAT eNOS produces NO. PVAT dysfunction represents a major mechanism for vascular dysfunction in aorta from dietinduced obese mice. We demonstrate for the first time that the PVAT eNOS is uncoupled under the condition of diet-induced obesity. The molecular mechanisms involve l-arginine deficiency because of arginase induction. Consistently, PVAT eNOS uncoupling can be reversed by a combination therapy of l-arginine supplementation and arginase inhibition.
Endothelial Dysfunction Versus PVAT Dysfunction
In aorta without PVAT, we observed no difference in acetylcholine-induced vasodilation between HFD-and NCD-treated mice (Figure 1) . At a first glance, this seems surprising. Several previous studies have demonstrated that diet-induced obesity leads to endothelial dysfunction in mouse aorta without PVAT. Mice fed with a rodent diet with 45 kcal% fat for 12 weeks impaired the acetylcholine-induced, endothelium-dependent vasorelaxation. 10, 11 However, the effect of diet-induced obesity on endothelial function is likely to be time-dependent. Longer treatment with HFD may induce compensatory mechanisms, leading to adaptation and relative normalization of endothelial function. After treatment of male C57BL/6J mice with inhibitor N G -nitro-l-arginine methyl ester (l-NAME). ***P<0.001, n=8. To detect PVAT NO production, NCD and HFD aorta samples were mounted backto-back on the same slide to guarantee identical staining conditions for the 2 samples (D). NO production in PVAT-containing aorta was determined by 4,5-diaminofluorescein diacetate (DAF-2 DA) staining. The confocal images shown are representative for 5 independent experiments with similar results. Fluorescence intensity was quantified after setting up the system (circa 5 minutes after adding acetylcholine; E).
HFD for 30 weeks, the acetylcholine-induced vasodilation remained completely normal in acetylcholine concentration ranges ≤100 nmol/L in the aorta. 12 In our study, the endothelial function of the aorta from mice treated with HFD for 20 weeks was also relatively normal ( Figure 1A) . Thus, our experimental setting may represent an ideal model for studying the contribution of PVAT to vascular dysfunction.
PVAT has been recently recognized as novel determinant in vascular biology. The role of PVAT in vascular function was first discovered by the observation of a PVAT-mediated decrease in contractile responses to noradrenaline in rat aorta. 13 Now it is known that PVAT attenuates the vascular responsiveness of several (hormonal) agonists, including phenylephrine, angiotensin II, serotonin, and endothelin-1. 14, 15 PVAT may regulate vascular tone by releasing adipokines, which can be regarded as an endocrine function. In addition, PVAT also exerts a more direct, local effect on the vascular wall via paracrine mechanisms. Composed mainly of adipocytes, PVAT releases a wide range of biologically active molecules that modulate vascular function.
14 Several PVAT-derived biologically active molecules with vascular effects have been identified, including adipokines, cytokines/chemokines, reactive oxygen species, and some gaseous molecules, including NO and H 2 S.
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Expression and Function of eNOS in PVAT
Previous studies have shown eNOS expression in adipose tissues 16 and in adipocytes. 17 Immunohistochemistry analysis has identified eNOS staining in adipocytes within PVAT. 18 Incubation of epididymal fat pads with leptin leads to eNOS activation and NO release. 19 This adipocyte-derived NO is supposed to be released into the interstitial fluid and may diffuse into the capillaries and adjacent arterioles causing vasodilation. 19 Indeed, an enhanced relaxant response of mesenteric artery and a leptin-mediated adaptative NO overproduction from mesenteric PVAT have been demonstrated at the early phase of diet-induced obesity in C57BL/6J mice. 20 In the present study, we confirmed that eNOS is expressed in PVAT (Figure 2) , and PVAT eNOS produces NO (Figure 1 ). PVAT-derived NO contributes to acetylcholine-induced vasodilation under normal conditions ( Figure I in the online-only Data Supplement). Under conditions of diet-induced obesity, NO production from PVAT eNOS is reduced, as shown in NO fluorescence imaging ( Figure 1D ), as well as in functional studies ( Figure 1B ). Our data suggest that eNOS uncoupling represents a molecular mechanism responsible for the obesity-induced reduction of PVAT NO production and vascular dysfunction of aortic ring segments with PVAT. Reversal of eNOS uncoupling with l-arginine in combination with an arginase inhibitor completely corrected the vascular dysfunction in PVAT-containing aorta from diet-induced obese mice ( Figure 6 ). It is noteworthy that all the pathological changes, including eNOS dephosphorylation, arginase upregulation, l-arginine deficiency, and eNOS uncoupling, were found only in PVAT, but not in the vascular wall itself. No evidence for changes in proliferation of smooth muscle cells was observed ( Figure IV in the online-only Data Supplement). This is consistent with results from functional studies that acetylcholineinduced vasodilation remained normal in PVAT-free aortas ( Figure 1A ).
Uncoupling of eNOS and Vascular Pathophysiology
Under physiological conditions, eNOS produces NO, which represents a key element in the vasoprotective function of the endothelium. Under pathological conditions, however, eNOS may become uncoupled (ie, uncoupling of O 2 reduction from NO synthesis), such that it no longer produces NO, but superoxide. 9, 21, 22 The phenomenon of eNOS uncoupling has been shown in different pathologies, including diabetes mellitus, hypertension, and atherosclerosis. 8, 9, 23 To date, the scientific interest of eNOS uncoupling studies has focused on eNOS in the endothelium. The present study is the first demonstrating eNOS uncoupling in PVAT.
Numerous mechanisms have been proposed to play a role in eNOS uncoupling. 21, 24 Among these, depletion of BH 4 , an essential cofactor for the eNOS enzyme, is likely to be a major cause for eNOS uncoupling and endothelial dysfunction. BH 4 can be oxidized by peroxynitrite and superoxide to 7,8-dihydrobiopterin, thereby leading to BH 4 deficiency. 25, 26 Another important cause of eNOS uncoupling is a deficiency of l-arginine because of upregulation of arginase expression/activity. In humans and mammals, there are 2 isoforms of arginases: arginase I and arginase II, which are encoded by 2 separate genes. 27 Studies performed with vascular endothelial cells suggest that these 2 isoforms share similar functions, that is, metabolizing l-arginine to urea and l-ornithine, whereby an arginase upregulation in endothelial cells limits l-arginine bioavailability for NO production, leading to endothelial dysfunction. 27 Uncoupling of eNOS is a crucial mechanism contributing significantly to endothelial dysfunction and atherogenesis. It not only reduces NO production, but also potentiates the preexisting oxidative stress. The overproduction of reactive oxygen species (eg, superoxide and subsequently peroxynitrite) by uncoupled eNOS in turn enhances oxidation of BH 4 and upregulation of arginase expression/activity, 28 creating a vicious circle.
Potential Mechanisms of Arginase Upregulation and l-Arginine Deficiency
The expression/activity of vascular arginases has been shown to be enhanced by a variety of stimuli, 29 including angiotensin II, 30 high glucose, 31 thrombin, 32 and oxidized low-density lipoprotein, 33 conditions that inevitably lead to vascular inflammation. We, therefore, investigated whether inflammation represents a cause of arginase upregulation and l-arginine deficiency in our model. It is known that PVAT produces a large variety of bioactive molecules that affect vascular function, including leptin, adiponectin, interleukin-6, and tumor necrosis factor-α. 34, 35 In PVAT of HFD mice, proinflammatory adipokines/cytokines (eg, leptin, interleukin-6, tumor necrosis factor-α, and interferon-γ) were upregulated, whereas anti-inflammatory adipokines/cytokines (eg, adiponectin and interleukin-10) were downregulated ( Figure III in the online-only Data Supplement). This is consistent with previous studies. [34] [35] [36] Diet-induced obesity also led to secretion of monocyte chemotactic protein 1 by adipocytes into the extracellular space where it induces monocyte recruitment into adipose tissue. 34, 37 Indeed, we observed an upregulation of monocyte chemotactic protein 1 in PVAT of HFD mice, which was associated with enhancement of macrophage markers ( Figure III in the online-only Data Supplement). Thus, macrophages may also contribute to the enhanced production of proinflammatory cytokines (eg, interleukin-6 and tumor necrosis factor-α) and the resulting PVAT inflammation ( Figure V in the online-only Data Supplement).
Coexistence of Uncoupled and Coupled eNOS
It is not surprising that l-NAME reduced NO production ( Figure 1D ), as well as superoxide production (Figure 3) , from PVAT eNOS in obese animals. eNOS uncoupling is not an all-or-none phenomenon. 9 Rather, uncoupled eNOS molecules and coupled eNOS proteins may exist in the same cell at the same time. Because of relative deficiency of BH 4 or l-arginine, part of the eNOS molecules become uncoupled, whereas some others may still remain coupled. 9 Such a situation has also been observed in the hypercholesterolemic apolipoprotein E-knockout mice, in which both superoxide and NO production by eNOS are detectable. 38 This also applies to our model with both coupled and uncoupled eNOS molecules existing in PVAT of obese mice.
Phosphorylation is a major posttranslational modification, with phosphorylation at serine 1177 being the most important positive modulation of eNOS activity. 39 The activation of eNOS catalytic function by serine 1177 phosphorylation is because of inhibition of calmodulin dissociation from eNOS and enhancement of the internal rate of eNOS electron transfer. 40 This phosphorylation is required for both the NO-producing activity of the coupled eNOS and the superoxide-producing activity of the uncoupled eNOS. The detrimental effects of superoxide produced by uncoupled eNOS do not overwhelm the protective role of eNOS-derived NO. This is true in the mouse model of atherosclerosis 38 and may also be the case in our model. Therefore, the net effect of reduced eNOS phosphorylation at serine 1177 ( Figure 2D ) is a reduction of NO production ( Figure V in the online-only Data Supplement).
Limitation of the Study
PVAT is a conglomerate of various cell types, including adipocytes, preadipocytes, and mesenchymal stem cells, embedded in a matrix that is invested with microvessels. 41 Although our results show clearly that eNOS dysfunction is evident in PVAT but not in the vascular wall, it is currently not possible to definitively distinguish the relative contribution of endothelial eNOS and PVAT eNOS in the present study. Moreover, microvessels present in PVAT also contain endothelial cells (Figure 2A ), albeit they only represent a minority of the eNOSpositive cells in PVAT; the majority are adipocytes. The relative contribution of endothelial eNOS and PVAT eNOS will be further addressed in future studies using knockout mice with cell type-specific eNOS deletion.
Clinical Implications
There is currently no effective therapy to treat vascular complications of obesity. Results from our study indicate that l-arginine supplementation and arginase inhibition could represent a new therapeutic strategy. Promising results have been achieved with arginase inhibitors, although only limited data from clinical studies are currently available. Smallscale proof-of-concept clinical studies have shown that local administration of arginase inhibitors improves vascular function in aged humans, 42 as well as in patients with coronary artery disease and type 2 diabetes mellitus, 43 heart failure, 44 or hypertension. 45 Larger clinical studies with systemic arginase inhibition are warranted.
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Conclusions
Diet-induced obesity leads to arginase induction in PVAT. The resulting l-arginine deficiency and eNOS uncoupling represents a novel mechanism underlying the vascular dysfunction in this model. Reversal of eNOS uncoupling by l-arginine and arginase inhibitors prevents obesity-induced vascular dysfunction, which may represent a novel therapeutic strategy for obesity-associated vascular disease.
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